---
title: "VYNE Therapeutics Inc. (VYNE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VYNE.US.md"
symbol: "VYNE.US"
name: "VYNE Therapeutics Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T16:08:43.344Z"
locales:
  - [en](https://longbridge.com/en/quote/VYNE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VYNE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VYNE.US.md)
---

# VYNE Therapeutics Inc. (VYNE.US)

## Company Overview

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [vynetherapeutics.com](https://vynetherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: D (0.63)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 156 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -24.96% |  |
| Net Profit YoY | 49.15% |  |
| P/B Ratio | 0.92 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 22546457.50 |  |
| Revenue | 454000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -63.16% | E |
| Profit Margin | -4726.21% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -24.96% | E |
| Net Profit YoY | 49.15% | B |
| Total Assets YoY | -54.14% | E |
| Net Assets YoY | -44.17% | E |
| Cash Flow Margin | 119.98% | C |
| OCF YoY | -24.96% | E |
| Turnover | 0.01 | E |
| Gearing Ratio | 4.78% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - VYNE Therapeutics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-24.96%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "49.15%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.92",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "22546457.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "454000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-63.16%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-4726.21%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-24.96%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "49.15%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-54.14%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-44.17%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "119.98%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-24.96%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "4.78%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.05 | 106/190 | - | - | - |
| PB | 0.92 | 44/190 | 0.71 | 0.49 | 0.23 |
| PS (TTM) | 49.66 | 141/190 | 37.00 | 34.18 | 18.08 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-08T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 33% |
| Hold | 2 | 67% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.68 |
| Highest Target | 2.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VYNE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VYNE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VYNE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VYNE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**